Mr. Paul Reid:

If the €350 million is broken down, €150 million of it was the National Treatment Purchase Fund, NTPF, and €200 million was HSE, and that was at the top level. As part of that there was some one-off funding, but in terms of making longer term, sustainable impacts on the waiting lists, part of it will be recurrent, which is what will carry forward into next year, to recruit specialists and address some of the specialist waiting lists we have. That will require funding into next year. That has been part of the dialogue and submission we have part of the Estimates process. Some of it does carry into next year and lead current funding for next year.